Fig. 3
Validation of our findings in publicly available microarray data. The ratio between GC-A and GC-B was calculated for independent validation cohorts of 20 systemic lupus erythematosus (SLE) patients with a type I interferon signature (IFN high) and 70 IFNhigh IFNβ-treated multiple sclerosis (MS) patients. This confirms our earlier findings of GC-A > GC-B in SLE and GC-B > GC-A in IFNβ-treated MS